Gaurav Sharma, MD

Hematologist-Oncologist serving rural Alabama @alcancercare | Hematology/Oncology @USAMCI |Internal Medicine @usacollegeofmed IMed School @KEMHOSPITAL

[Oncology Brothers @OncBrothers]

TDXd now @US_FDA ✅ in neoadjuvant and adjuvant high risk residual HER2+ breast cancer based off DESTINYBreast05 and DESTINYBreast11:

- ⬆️ pCR & iDFS w/ TDXd
- Timings of RT did NOT impact the incidence or severity of ILD
- New Soc for high risk disease!

#bcsm #OncTwitter

[Toni Choueiri, MD @DrChoueiri]

JUST IN: @FDA approves adjuvant PD-L1 inhibitor Atezolizumab in Muscle-Invasive Bladder Cancer post surgery & ctDNA MRD (+) by @NateraGenetics Signatera CDx approved as companion diagnostic.

MRD-guided adjuvant therapy is moving into practice in Bladder Cancer!

FDA link: https://t.co/DPjLN6Ag2Z

[Jonathan Friedberg @DrJFriedberg]

Good Oncologist: Doctoring Lessons From the Art of Oncology | @JCO_ASCO
https://t.co/dKOHddmNbM

[Toni Choueiri, MD @DrChoueiri]

JUST IN: The report we always look for every year: CANCER STATISTICS, 2026

New milestone with 5y Survival of 70%!!! Still a lot of room to improve but also excellent progress !

@AmericanCancer @CACancerJournal @DanaFarber

https://t.co/ZtFDhFOGgU

[Toni Choueiri, MD @DrChoueiri]

HIGHEST RANKED TRIALS for 2025

TOP 10 #cancerclinicaltrials in 2025 w/MOST Impact

1/ #DeLLphi304 @NEJM led by #Zeusofoncology @g_mountzios @HenryDunantGR : In relapsed SCLC post-platinum, BiTE DLL-3 Tarlatamab improved mOS vs. Chemo (13.6 vs 8.3 m, HR 0.60). PFS and in cancer-related dyspnea also improved.

https://t.co/dlIvlySUT9

[Paolo Tarantino @PTarantinoMD]

The @US_FDA approves T-DXd/pertuzumab for the first-line treatment of HER2+ metastatic breast cancer, based on the DESTINY-Breast09 trial. Data on the T-DXd monotherapy arm of the study pending and highly awaited. https://t.co/VKRtZgvx8j

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

Peripheral blood smear of a 30 yr old with fever, weight loss, and fatigue 😭

These cells are enough to make a diagnosis!

📸 @ASH_hematology image bank

[JAMA @JAMA_current]

H-1B visa–sponsored physicians are twice as prevalent in rural counties and nearly 4 times as common in high-poverty areas, highlighting the potential harm of rising visa costs to health care access.

https://t.co/TwsCbCc4nT

[Oncology Brothers @OncBrothers]

#SABCS25 Day 2 Highlights:

1. #lidERA: SERD in Adj HR+

2. #ALLTO: Adj ET in HR+/HER2+

3. #ASCENT07: Saci in HR+ mBC

4. #HER2Climb05: Tucatinib in 1L HER2+ mBC

5. #DB11: TDXd in NeoAdj Her2+

6. #DB05: TDXd in Adj Her2+

@SABCSSanAntonio #bcsm #OncTwitter @OncoAlert

1/7

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH25 #mmsm @ASH_hematology

Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes

➡️ https://t.co/IbtbIugiTO

[NEJM @NEJM]

Original Article: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (MajesTEC-3 phase 3 trial) https://t.co/DixpsZY8uT

#ASH25 | @ASH_hematology

[Gaurav Sharma, MD @hemeonc_doc]

In the midst of chaos, good news today!

[Dr Sarah Sammons @drsarahsam]

Day 2 ESMO Breast Cancer Notes #bcsm

[Gaurav Sharma, MD @hemeonc_doc]

Great read for those starting in community practice or academia.

Eight Aspects of Oncology That Aren’t Taught in Training—And Tips for How to Handle Them | ASCO Connection https://t.co/jpqfjUexwE

[Breelyn Wilky, MD 🎗 @breelynwilkyMD]

We are hiring @CUCancerCenter for #sarcoma faculty! Lots of patients, cutting edge clinical trials, a phenomenal multidisciplinary team, and all this with beautiful mountains to play in! DM me for details and feel free to share!

[Dr. Estela Rodriguez @Latinamd]

On this day, patients with #HER2+ #lungcancer got access to the first oral targeted therapy for HER2+ disease. -#zongertinib
➡️Beamion trial 1L: ORR was 75% with 58% having a DOR ≥ 6 mos.
➡️previously treated with HER2-targeted ADC, ORR was 44% with 27% having a DOR ≥ 6 months. #lcsm @Exon20Group

[Sakditad “Tew” Saowapa, MD @SakditadMD]

🩺 “Artful Oncology” @ASCO_OP: a psychosocial curriculum for Heme/Onc fellows.

📚 4-part: Didactics, narrative medicine, comms training, survivorship groups
📈 Comms skills ↑ from 4.4 → 7.4
🧠 PBS (attitudes) improved
😌 Burnout stable
🙌 Sessions rated 4.6/5

🔗 https://t.co/xgQz8Y8TNX

@oncodaily @OncoAlert @IMG_Oncologists @HemOncFellows
@ASCO

[Gaurav Sharma, MD @hemeonc_doc]

“What an honor to receive the Dundie Award for Best Fellow!”

[Gaurav Sharma, MD @hemeonc_doc]

@cancerassassin1 @USAMitchellCtr @ESMO_Open @EAntonarakis @UMNCancer @RueschCenter @benweinbergmd @AnwaarSaeed3 @CSCancerCenter @ViChiuMDPhD @carisls Thanks! what a privilege to work with you and all the co-authors on this.

[Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1]

Congratulations to @hemeonc_doc Dr. Gaurav Sharma who is completing his heme-onc fellowship this month @USAMitchellCtr! Paper on uncovering IO biomarkers for anal cancers - published today @ESMO_Open https://t.co/Ecd3ssJVcL